News / Press Release

What Are the Costs Involved in Receiving an Investigational Drug?

April 29, 2017

If they are selected to receive an investigational drug, patients can expect to receive that drug free of charge. In some cases, other costs associated with the treatment itself may pop up, and patients should check with their insurer to see if those additional costs are covered prior to beginning the treatment regimen.

Additional costs associated with treatment can come from a few different places. If the drug causes certain side effects, for example, patients may need to receive a prescription for another drug to mitigate those side effects. Common side effects associated with oncology treatments can include:

The degree to which you might experience side effects from a cancer drug normally depends on the following:

Costs From the Pharmaceutical Company

The cost of moving an investigative drug through the regulatory system, including the clinical trial drug investigation itself, is high. In some cases, a pharmaceutical company may file a request with the FDA to charge you to use the drug. These charges would include the direct cost of making the investigational drug available, including manufacturing and shipping, as well as indirect costs, such as reporting on the drug’s efficacy and or a review from an institutional review board.

There may also be a cost associated with actually administering the investigational drug. This does not require FDA authorization. Such costs could end up being your responsibility. Again, it’s important to check with your insurer prior to beginning treatment so you don’t end up with any unexpected costs.

For more information about investigational new drugs, patients and physicians can take a look at the NCI’s PDQ database to track the status of ongoing studies. NCI's Cancer Trials website, along with information specialists at NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237), are also available to provide further information.

About Translational Drug Development (TD2)

TD2 is an oncology development organization that provides innovative services for oncology-focused companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncology diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2’s suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit www.TD2inc.com.

About TD2

TD2 is an oncology development organization that provides innovative services for oncology-focused companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncology diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2’s suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit www.TD2inc.com.

Contact
Tara Franks
602-358-8322
Get free tips, tools and resources by subscribing to the TD2 Newsletter: